礼来公司的争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

2026
宾夕法尼亚州就涉嫌胰岛素价格串通起诉胰岛素制造商和药品福利管理机构
提起诉讼
宾夕法尼亚州对礼来公司、Novo Nordisk Inc.、Sanofi-Aventis US LLC 及数家药品福利管理机构提起诉讼，指控这些公司串通抬高胰岛素价格。诉讼要求进行结构性改革、支付赔偿金及罚款。相关指控涉及胰岛素定价以及制造商和药品福利管理机构双方的角色。该案系由州政府提起的民事诉讼；起诉本身并不确立责任，相关主张仍属有待通过法律程序解决的指控。
宾夕法尼亚州起诉 Eli Lilly and Co.、Novo Nordisk Inc.、Sanofi-Aventis US LLC 及数家药品福利管理机构，指控它们串通抬高胰岛素价格。诉讼要求进行结构性改革、支付赔偿金及罚款。
来源摘录
- Last week, Pennsylvania sued a group of pharmaceutical companies and PBMs for allegedly colluding to raise insulin prices unnecessarily.
- The pharmaceutical companies included in the Pennsylvania case are Eli Lilly and Co., Novo Nordisk Inc., and Sanofi-Aventis US LLC. Several PBMs are included as defendants, including Express Scripts, Caremark, and Optum RX.
- The state’s lawsuit seeks to institute “structural changes to ensure the companies lower costs to fair market prices and enable options for patients,” restitution for Pennsylvanians harmed by the scheme, and payments including financial penalties paid by the companies and the costs of the state’s investigation and lawsuit.
来源
2025
印第安纳州起诉礼来公司涉嫌胰岛素价格操纵
提起诉讼
印第安纳州于12月31日在莱克县高等法院提起诉讼，指控礼来公司与药品福利管理机构合谋，通过秘密返利人为抬高胰岛素标价，部分胰岛素产品售价约300至700美元。礼来表示已采取行业领先措施降低胰岛素成本，包括将患者自付费用上限设为每月35美元并将标价下调70%。
品牌回应
- 否认 — Eli Lilly and Company
  In a statement to WFYI, a company spokesperson said Lilly has taken “industry-leading” steps to lower insulin costs, including capping patient out-of-pocket costs at $35 per month and cutting list prices by 70%.
来源摘录
- Indiana is suing Indianapolis-based Eli Lilly and Company, accusing the pharmaceutical giant of inflating insulin prices through a coordinated pricing scheme involving secret rebates.
- The lawsuit, filed Dec. 31 in Lake County Superior Court, builds on legal action Rokita took in March 2024 against other drug manufacturers and pharmacy benefit managers over insulin pricing.
- The lawsuit alleges Lilly conspired with pharmacy benefit managers to artificially inflate the sticker prices of insulin.
来源

宾夕法尼亚州就涉嫌胰岛素价格串通起诉胰岛素制造商和药品福利管理机构

提起诉讼

宾夕法尼亚州对礼来公司、Novo Nordisk Inc.、Sanofi-Aventis US LLC 及数家药品福利管理机构提起诉讼，指控这些公司串通抬高胰岛素价格。诉讼要求进行结构性改革、支付赔偿金及罚款。相关指控涉及胰岛素定价以及制造商和药品福利管理机构双方的角色。该案系由州政府提起的民事诉讼；起诉本身并不确立责任，相关主张仍属有待通过法律程序解决的指控。

宾夕法尼亚州起诉 Eli Lilly and Co.、Novo Nordisk Inc.、Sanofi-Aventis US LLC 及数家药品福利管理机构，指控它们串通抬高胰岛素价格。诉讼要求进行结构性改革、支付赔偿金及罚款。

来源摘录

Last week, Pennsylvania sued a group of pharmaceutical companies and PBMs for allegedly colluding to raise insulin prices unnecessarily.
The pharmaceutical companies included in the Pennsylvania case are Eli Lilly and Co., Novo Nordisk Inc., and Sanofi-Aventis US LLC. Several PBMs are included as defendants, including Express Scripts, Caremark, and Optum RX.
The state’s lawsuit seeks to institute “structural changes to ensure the companies lower costs to fair market prices and enable options for patients,” restitution for Pennsylvanians harmed by the scheme, and payments including financial penalties paid by the companies and the costs of the state’s investigation and lawsuit.

印第安纳州起诉礼来公司涉嫌胰岛素价格操纵

提起诉讼

印第安纳州于12月31日在莱克县高等法院提起诉讼，指控礼来公司与药品福利管理机构合谋，通过秘密返利人为抬高胰岛素标价，部分胰岛素产品售价约300至700美元。礼来表示已采取行业领先措施降低胰岛素成本，包括将患者自付费用上限设为每月35美元并将标价下调70%。

品牌回应

否认 — Eli Lilly and Company
In a statement to WFYI, a company spokesperson said Lilly has taken “industry-leading” steps to lower insulin costs, including capping patient out-of-pocket costs at $35 per month and cutting list prices by 70%.

来源摘录

Indiana is suing Indianapolis-based Eli Lilly and Company, accusing the pharmaceutical giant of inflating insulin prices through a coordinated pricing scheme involving secret rebates.
The lawsuit, filed Dec. 31 in Lake County Superior Court, builds on legal action Rokita took in March 2024 against other drug manufacturers and pharmacy benefit managers over insulin pricing.
The lawsuit alleges Lilly conspired with pharmacy benefit managers to artificially inflate the sticker prices of insulin.